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ABSTRACT
Objective: To determine the clinical phenotype and outcome in hepatitis E virus–associated
neuralgic amyotrophy (HEV-NA).
Methods: Cases of NA were identified in 11 centers from 7 European countries, with retrospec-
tive analysis of demographics, clinical/laboratory findings, and treatment and outcome. Cases of
HEV-NA were compared with NA cases without evidence of HEV infection.
Results: Fifty-seven cases of HEV-NA and 61 NA cases without HEV were studied. Fifty-six of 57
HEV-NA cases were anti-HEV IgM positive; 53/57 were IgG positive. In 38 cases, HEV RNA was
recovered from the serum and in 1 from the CSF (all genotype 3). Fifty-one of 57 HEV-NA cases
were anicteric; median alanine aminotransferase 259 IU/L (range 12–2,961 IU/L); in 6 cases,
liver function tests were normal. HEV-NA cases were more likely to have bilateral involvement
(80.0% vs 8.6%, p , 0.001), damage outside the brachial plexus (58.5% vs 10.5%, p , 0.01),
including phrenic nerve and lumbosacral plexus injury (25.0% vs 3.5%, p 5 0.01, and 26.4% vs
7.0%, p50.001), reduced reflexes (p50.03), sensory symptoms (p50.04) with more extensive
damage to the brachial plexus. There was no difference in outcome between the 2 groups at 12
months.
Conclusions: Patients with HEV-NA are usually anicteric and have a distinct clinical phenotype,
with predominately bilateral asymmetrical involvement of, and more extensive damage to, the
brachial plexus. Involvement outside the brachial plexus is more common in HEV-NA. The relation-
ship between HEV and NA is likely to be causal, but is easily overlooked. Patients presenting with
NA should be tested for HEV, irrespective of liver function test results. Prospective treatment/
outcome studies of HEV-NA are warranted. Neurology® 2017;89:1–9
GLOSSARY
ALT 5 alanine aminotransferase; gt3 5 genotype 3; HEV 5 hepatitis E virus; LFT 5 liver function test; MRC 5 Medical
Research Council; NA 5 neuralgic amyotrophy.
The clinical syndrome of neuralgic amyotrophy (NA) has been recognized since the late 19th
century1 and defined by Parsonage and Turner in 1948.2 Patients generally present with severe
pain, usually in the shoulder, most often preceded by symptoms suggestive of an infection.3 In
2006, a large cohort study3 found a subgroup of patients with NA who were mostly middle-aged
men with extensive peripheral nervous system damage and abnormal liver function tests (LFTs),
for which no explanation could be found at the time. Recently, NA occurring in the context of
hepatitis E virus (HEV-NA) infection has been reported.4,5
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HEV is a pathogen of global significance
and is endemic in developed European na-
tions6 where hepatitis E is caused mainly by
HEV genotype 3 (gt3), which is a porcine
zoonosis.7 In some developed countries,
HEV infection is very common. In England,
there are estimated to be 100,000 infections
per annum,8 but only a small minority of pa-
tients develop clinically apparent hepatitis,
and most cases are either asymptomatic or
unrecognized.7 Several studies have described
a range of neurologic injuries associated with
HEV infection, including NA.4,5,9 To date, 31
cases of hepatitis E–associated NA have been
described in the literature, mostly European
patients with gt3 infection.5 We investigated
whether such patients have a different clinical
phenotype and outcome compared with pa-
tients with idiopathic NA.
METHODS Patients. Cases of NA were eligible for inclusion if
they had been tested for HEV. Cases of NA were identified in 11 dif-
ferent centers from 7 countries, including the Netherlands, United
Kingdom, Switzerland, Germany, France, Belgium, and Italy. Sixteen
patients have been reported before.4,9–16 HEV-associated cases were
detected through a combination of routine and sporadic HEV testing
in patients withNA. In addition to these prospectively tested patients,
we included 38 patients from an earlier Dutch study of antecedent
infections and immunogenetic factors in NA.4 HEV-negative pa-
tients came mainly from the latter study and 2 participating centers
that increasingly test routinely for HEV in cases of NA. Data cap-
tured from the clinical records were a predefined list of variables and
included demographics, clinical and laboratory findings, and treat-
ment and outcome.We assessed neurologic outcomes by theMedical
Research Council (MRC) sum-score of the 3 weakest muscles
(ranging from 05 full paralysis to 55 normal strength) at 6 and 12
months and by the Functional Disability Score (ranging from 05 no
complaints to 5 5 in need of continuous care) at final follow-up.17
Most of our cases were tested for other infections, including hepatitis
A, B, or C viruses, Epstein-Barr virus, Cytomegalovirus, Borrelia
burgdorferi, or HIV when clinically indicated in the workup of liver
function abnormalities or in the differential of NA by the local
treating physicians. In a quarter of the patients with HEV-NA, all the
above infections were excluded.
Case definition of NA. We used the following case definition,
adapted from van Alfen et al.,18 to diagnose NA:
1. (Sub) acute onset (over hours or days)
2. Initial pain with numerical rating scale score $7
3. Multifocal distribution of neurologic injury centered on the
brachial plexus
4. Monophasic course, with slow recovery
5. Preceding direct trauma, malignancy, and radiation excluded.
Confirmatory neurophysiology studies were not mandatory
for defining a case, but were performed in most patients.
Definition of hepatitis E. We defined cases of hepatitis E by
a combination of serologic and molecular assays at all centers.
Acute or recent HEV infection was diagnosed when19:
1. serum anti-HEV IgM and anti-HEV IgG assays were both
reactive and/or
2. HEV RNA was detected in the serum using RT-PCR.
Because of the retrospective and multicenter nature of the
study differing, but validated, laboratory methods were used in
participating centers.
Statistics. We compared the demographics, clinical/laboratory
findings, and outcome of cases with evidence of HEV infection
at the start of their neurologic illness to cases without evidence
of HEV infection. We conducted linear, logistic, and ordered
logistic regressions using R software (R Development Core Team,
2015). We considered a 2-sided p value ,0.05 to be statistically
significant. Missing at random was assumed, and complete case
analysis was used to handle missing data.
Ethics. This was a descriptive retrospective study of anonymized
previously documented data. Ethical approval was not required.
RESULTS We documented 118 patients who fulfilled
the case definition of NA and had been tested for HEV.
Fifty-seven of these had evidence of current/recent
HEV infection at the start of their neurologic illness. All
but one were anti-HEV IgM positive; 54/57 were anti-
HEV IgG positive. In 38 (66.6%) cases, HEV RNA
was recovered from the serum and in 1 case from the
CSF. In the 25 cases in which genotyping was suc-
cessful, we identified HEV gt3. One patient was anti-
HEV IgM negative but IgG and PCR positive. Sixty-
one NA cases had no evidence of acute or recent
HEV infection. Ten of these were anti-HEV IgG
positive, consistent with previous infection. Tests for
other causes of viral hepatitis were negative, excepting 1
patient with acute HEV infection who had pre-existing
chronic hepatitis B virus infection. None of the patients
who we serologically tested more extensively had
evidence of an additional concomitant infection.
Clinical phenotype. We found the majority of NA
cases to be middle-aged men (table e-1 at
Neurology.org). HEV-NA cases were slightly older
(median age 51 years) than cases not associated with
HEV (median age 44 years, p, 0.01). There were no
differences between the 2 groups in sex, history of
autoimmune disease, antecedent events, or time from
symptom onset to presentation (table e-1).
At presentation ( T1table 1 and figure), HEV-NA cases
were more likely to have bilateral F1involvement of the
brachial plexus (80.0%) compared with cases not associ-
ated with HEV (8.6%, p , 0.001); neurologic involve-
ment outside the brachial plexus (p, 0.001), including
phrenic nerve and lumbosacral plexus involvement (p,
0.01); and diminished tendon reflexes in the affected
limb(s) (p 5 0.03). Some muscles were more often
involved, including right supraspinatus (p5 0.01), right
infraspinatus (p 5 0.01), right deltoid (p 5 0.02), and
triceps bilaterally (p5 0.01 and 0.02).We found a high-
er proportion of muscles involved in the HEV-NA cases
and with more frequent involvement of the upper trunk
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(either side) and right middle and lower trunk (table 1),
suggesting more extensive/severe nerve injury in this
group. At presentation, patients with HEV-NA were
more likely to have (had) myalgia in the upper and lower
limbs (p 5 0.02). Hoarseness (recurrent laryngeal nerve
involvement), peripheral facial nerve palsy, and trigemi-
nal neuropathy were also reported in the HEV-NA
group (table 1).
Table 1 Neurologic features at presentation
HEV1 HEV2 p Value (CI)
Hand dominance
Left:right 4/37 (10.8%) 7/50 (14%) 0.7 (0.19 to 2.75)
Median NRS pain score (range) 9 (6–10) 9 (5–10) 0.57 (20.75 to 0.41)
Median duration in days of initial pain
(range)
15 (0.25–365) 20 (1–80) 0.6 (213.81 to 23.62)
Side affected
Dominant 2/10 (20%) 21/53 (39.6%) 0.25 (0.05 to 1.70)
Nondominant 4/10 (40%) 28/53 (52.8%) 0.46 (0.14 to 2.32)
Bilateral 44/55 (80%) 5/58 (8.62%) ,0.001 (14.82 to 146.21)
Median MRC sum-score; 3 weakest muscles
(range)
10 (1–15) 10 (2–13) 0.84 (0.53 to 2.21)
Pattern of weakness
Upper trunk: right 39/45 (86.7%) 34/59 (57.6%) ,0.001 (1.85 to 14.12)
Middle trunk: right 23/45 (51.1%) 12/59 (20.3%) ,0.001 (1.76 to 9.96)
Lower trunk: right 12/45 (26.7%) 5/59 (8.5%) 0.02 (1.33 to 13.28)
Upper trunk: left 37/45 (82.2%) 30/59 (50.8%) ,0.001 (1.40 to 5.46)
Middle trunk: left 22/45 (48.9%) 20/58 (34.5%) 0.14 (0.82 to 4.07)
Lower trunk: left 6/45 (13.3%) 7/59 (11.9%) 0.82 (0.34 to 3.7)
Muscle involvement
Supraspinatus: right 24/35 (68.6%) 19/48 (39.6%) 0.01 (1.35 to 8.59)
Infraspinatus: right 26/39 (66.7%) 19/48 (39.6%) 0.01 (1.28 to 7.55)
Deltoid: right 27/43 (62.7%) 20/52 (38.4%) 0.02 (1.19 to 6.32)
Triceps: right 21/43 (48.8%) 12/51 (23.5%) 0.01 (1.30 to 7.67)
Triceps: left 18/45 (40.0%) 9/50 (18%) 0.02 (1.22 to 8.03)
Median proportion of muscles involveda
(range)
0.36 (0.06–0.93) 0.19 (0.03–0.63) ,0.001 (1.31 to 2.98)
Scapula dyskinesia 31/56 (55.4%) 41/60 (68.3) 00.15 (0.27 to 1.22)
Glenohumeral complications 9/53 (17%) 8/59 (13.6%) 0.61 (0.46 to 3.75)
Sensory symptoms 41/51 (80.4%) 38/61 (62.3%) 0.04 (1.07 to 6.09)
Myalgia 9/48 (18.8%) 1/60 (1.7%) 0.02 (2.42 to 256.09)
Involvement outside brachial plexus
Lumbosacral 14/53 (26.4%) 4/57 (7%) 0.01 (1.57 to 17.79)
Phrenic 13/53 (24.5%) 2/57 (3.5%) 0.01 (2.30 to 59.22)
Facial 1/53 (1.9%) Nil NA
Other 5/53 (7.5%)b 1/57 (1.8%)c 0.18 (0.65 to 91.04)
Any 32/53 (60.3%) 6/57 (10.5%) 0.00 (4.64 to 35.65)
Tendon reflexes
Diminished/absent 22/55 (40%) 12/58 (20.7%) 0.03 (1.13 to 6.02)
Normal 30/55 (54.5%) 42/58 (72.4%) 0.05 (0.21 to 0.99)
Abbreviations: CI 5 confidence interval; HEV 5 hepatitis E virus; MRC 5 Medical Research Council; NA 5 not available;
NRS 5 numerical rating scale.
aNumber of paretic muscles/total number of muscles tested (Kruskal-Wallis test).
bCerebral (n 5 1), trigeminal (n 5 1), and recurrent laryngeal (n 5 3) nerve involvement.
cCervical.
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In patients presenting with HEV infection, the
biochemical evidence of hepatitis was modest: the
median serum bilirubin level at presentation (T2 table
2) was 13 mmol/L and alanine aminotransferase
(ALT) 259.5 IU/L. Six of the 57 (10.5%) patients
with hepatitis E had clinically detectable jaundice. In
5 patients, this was mild (bilirubin 50–100 mmol/L).
In 1 patient, the bilirubin level was 346 mmol/L;
however, this was in the context of pre-existing de-
compensated chronic hepatitis B. In 6 HEV-
associated cases, the LFTs were normal.
Twenty-four HEV-associated cases underwent
lumbar puncture, 6 of whom had a CSF pleocytosis
with white cell counts .10/mm3 and protein
.0.42 g/L. HEV RNA was detected in the abnormal
CSF of 1 patient infected by HEV gt3.15 Five (83%)
patients with CSF pleocytosis had involvement of
nerves outside the brachial plexus, i.e., phrenic nerve
(n 5 3), lumbosacral plexus (n 5 3), and trigeminal
neuropathy (n5 1). The median Functional Disabil-
ity Score was not different to that in patients without
CSF pleocytosis. CSF samples from 7 patients in the
HEV negative group were all normal.
Outcome and response to treatment. Functional Dis-
ability Scores at final follow-up were no different
between the 2 groups ( T3table 3). The MRC sum-
scores of the 3 weakest muscles were lower in the
Figure Hepatitis E virus–associated imaging
(A) Typical plexplots from (a) hepatitis E virus (HEV)-associated case; (b) non–HEV-associated case of neuralgic amyotrophy.
Normal neurologic tissues of the brachial plexus are shown in green, mildly affected in yellow, moderately affected in
orange, and severely affected in red. HEV-associated cases of neuralgic amyotrophy are characterized by bilateral, patchy,
asymmetrical damage to the brachial plexus. These figures were derived from clinical and electrophysiologic data of
patients included in the study. (B) Typical clinical phenotype of HEV-associated neuralgic amyotrophy. HEV-associated
bilateral neuralgic amyotrophy at presentation (a, b) and after 6months (c). Bilateral winged scapula, caused by long thoracic
neuropathy, is already evident at rest (a) but is accentuated when the patient raises his arms forward (b). The dotted black
ovoid indicates the area of hypoesthesia (axillary nerve). Mild atrophy of right deltoid (*) and infraspinatus (**) muscles can
be appreciated 12 days after paresis onset (a) but becomes more prominent after 6 months (c). (C and D) MRI in HEV-as-
sociated neuralgic amyotrophy. (C) Brachial plexus MRI at presentation of HEV-associated bilateral neuralgic amyotrophy.
Reformatted coronal maximum intensity projection T2 SPACE with fat suppression shows thickening and hyperintensity
(red arrows) of the postganglionic C6 root. NA 5 neuralgic amyotrophy.AU2
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patients with HEV-NA at 6 months (p 5 0.02),
but there was no difference at 12 months. There
was no difference in the median time from onset to
resolution of symptoms. HEV-NA cases were more
likely to have received immunomodulatory therapy
(58.3%) than non–HEV-associated cases (37.5%,
p 5 0.04). Twenty-two HEV-NA cases (38.6%)
were given oral corticosteroids and 11 (19.3%) IV
immunoglobulin (Ig). Of the HEV-negative cases,
21 (34.4%) patients received oral prednisolone and
1 received methylprednisolone. There were no
differences in outcomes between cases with and
without HEV infection treated with prednisolone
or methylprednisolone, as determined by the MRC
sum-scores at 6 and 12 months and Functional
Disability Score at final follow-up. No adverse
events leading to discontinuation of corticosteroids
were observed in either group. HEV-NA cases used
opioid and neuropathic analgesics more frequently,
and pain control was better (p 5 0.04) than in the
HEV-negative cases.
In the HEV-NA group, 4 patients were treated
with ribavirin within a few days of symptom onset
(table e-2). Of these patients, 2 also received IVIg,
and the other 2 patients received oral corticosteroid
therapy. The outcome was variable. Of the 11
HEV-NA cases that received treatment with IVIg, 4
patients were cotreated with oral corticosteroids and
2 with ribavirin. There were no differences in the final
Functional Disability Score in these eleven patients
compared with the HEV-NA group as a whole
(p5 0.12). However, compared with patients within
the group who received any immunomodulatory
therapy (n 5 28), patients treated with IVIg had an
improved mean Functional Disability Score at final
follow-up (p 5 0.039), confirmed by the ordered
logistic regression analysis of individual scores (p 5
0.041). Most (7/11) patients treated with IVIg were
from 1 center (Lugano, Switzerland) and received
a 5-day course of treatment at a dose of 0.4 g/kg/d.
IVIg treatment was well tolerated, and in most cases,
pain improved or disappeared within 10 days of starting
therapy.
DISCUSSION HEV-NA appears to have a distinc-
tive clinical phenotype. Patients are older, have
bilateral and more extensive involvement of the
brachial plexus, and are more likely to have nerve
injury outside the brachial plexus (phrenic nerve
and lumbosacral plexus) compared with NA
cases without HEV infection. The clinical
phenotype of HEV-NA may indicate the
Table 2 Investigations
aHEV1 HEV2 p Value (CI)
Median ALT at presentation (range) 259.5 (12–2961) 23 (7–396) ,0.001 (426.81–853.96)
Median bilirubin at presentation (range) 13 (0.7–346) 6 (1–27) ,0.001 (8.32–41.49)
Median ALKP at presentation (range) 149 (4–659) 68 (31–155) ,0.001 (55.95–126.10)
CSF WBC ‡10/mm3 6/24 (25%) 0/7 (0%) NA
CSF protein >0.42 g/L 15/22 (68.18%) 2/6 (33.33%) 0.14 (0.67–36.75)
CSF HEV PCR1 1/11 0/1 NA
Cervical spine MRI
Root compression 2/30 (6.7%) 1/11 (9.1%) 0.79 (0.06–16.35)
Myelopathy Nil Nil NA
Degenerative 8/30 (26.7%) 2/11 (18.2%) 0.58 (0.33–12.26)
Normal 20/30 (66.7%) 8/11 (72.7%) 0.71 (0.14–3.27)
Brachial plexus MRI
GD enhancement 3/17 (17.6%) Nil NA
Plexus swelling 2/17 (11.7%) 1/5 (20%) 0.32 (0.01–7.18)
Normal 12/17 (70.6%) 4/5 (80%) 0.82 (0.03–8.32)
Abbreviations: ALKP 5 alkaline phosphatase; ALT 5 alanine aminotransferase; CI 5 confidence interval; GD 5 gadolinium;
HEV 5 hepatitis E virus; NA 5 not available; WBC 5 white blood count.AU3
Normal range: bilirubin 5 3–17 mmol/L; ALT 5 ,41 IU/L; ALKP 5 40–160 IU/L; CSF 5 WBC ,10/mm3, protein
0.12–0.42 g/L.
Electrophysiologic examination was not different between the 2 groups with regard to the presence of findings suggestive
of axonal loss (30/39 [77%] vs 49/56 [87%], not significant [NS]) and demyelinating pathology (3/39 [7%] vs 2/48 [4%],
NS). Because of the retrospective nature of the study and institutional differences in daily practice, the timing of the
electrophysiologic studies was very heterogeneous (HEV positives: median time to electrophysiologic examination 90,
range 3–850 days; HEV negatives: median 40, 5–330 days) and should be interpreted with caution.AU4
a Thirty-six patients were HEV PCR positive in the serum and were HEV gt3 when sequencing was possible (n 5 24).
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involvement of nerve roots as well. These
observations extend previous findings of bilateral
involvement published in case reports and small
case series of HEV-associated NA in developed
countries.4,5,9–11,15,16 Among the HEV-NA cases
we describe, neurologic illnesses dominated the
clinical picture. Most patients were anicteric with
mostly only mildly abnormal LFTs, which quickly
returned to the normal range (data not shown).
The diagnosis of HEV in such cases is easily
overlooked.
The exact pathophysiologic mechanism of NA
is unknown. Indirect evidence points to a multifac-
torial disorder with an innate susceptibility to
the disease and one or more external trigger(s)
such as antecedent infections and/or a mechanical
factor such as strenuous exercise.3,20 Our data
support the suggested relationship between an
antecedent HEV infection and NA. Most patients
with HEV-NA were viremic when tested within 2
weeks after symptom onset, but a subgroup of
HEV-IgM–positive patients was RNA negative
Table 3 Treatment and outcomes
HEV1 HEV2 p Value (CI)
Median time (range) from presentation to final
follow-up, mo
11.5 (1–179) 12 (3–110) 0.94 (27.95 to 8.62)
Median NRS pain score at follow-up (range) 3 (0–6) 3 (0–10) 0.54 (21.14 to 0.60)
Median MRC sum-score (range)a
At 6 moa 11 (5–15) 13 (6–15) 0.02 (0.10 to 0.83)
At 12 moa 13 (11–15) 14 (8–15) 0.64 (0.18 to 2.13)
Immunomodulatory treatment
Treatedb 28/48 (58.3%) 21/56 (37.5%) 0.04 (1.07 to 5.20)
Oral corticosteroids 22/48 (45.8%) 21/56 (37.5%) 1.00 (0.45 to 2.22)
IV methylprednisolone 0/48 (0%) 1/56 (1.79%) NA
IVIg 11/48 (22.9%) Nil NA
Antiviral treatment
Ribavirin 4/50 (8%) Nil NA
Analgesics
Paracetamol 35/52 (67.31) 46/56 (82.14%) 0.08 (0.18 to 1.08)
Nonsteroidal anti-inflammatory drugs 33/51 (64.71%) 47/57 (82.46%) 0.04 (0.16 to 0.94)
Opioids 29/48 (60.42%) 23/56 (41.07%) 0.05 (1.01 to 4.87)
neuropathic analgesia (tricyclic antidepressant,
duloxetine, gabapentin)
26/49 (53.06%) 16/58 (27.59%) 0.01 (1.34 to 6.75)
Successful pain relief 27/46 (58.7%) 21/55 (38.18%) 0.04 (1.04 to 5.19)
Functional Disability Score at final follow-up
0 5 no complaints 12/51 (23.53%) 8/58 (13.79%) 0.19 (0.72 to 5.35)
1 5 complaints but no restrictions 10/51 (19.61%) 20/58 (34.48%) 0.09 (0.19 to 1.10)
2 5 restrictions but no help in daily life 26/51 (50.98%) 29/58 (50%) 0.92 (0.49 to 2.21)
3 5 needs help in daily life but independent 2/51 (3.92%) 0/58 (0%) NA
4 5 not independent, requires help regularly 1/51 (1.96%) 1/58 (1.72%) 0.93 (0.04 to 29.33)
5 5 in need of continuous care 0/51 (0%) 0/58 (0%) NA
Comparison of mean scores 1.41 1.41 0.99 (20.34 to 0.33)
Comparison of outcomes (0–5) as a wholea 0.86 (0.52 to 2.19)
Median time (range) from onset to complete
resolution of symptoms, mo
3 (1–120) 12 (3–26) 0.85 (225.15 to 30.39)
Abbreviations: CI 5 confidence interval; HEV 5 hepatitis E virus; MRC 5 Medical Research Council; NA 5 not available;
NRS 5 numerical rating scale (1–10).
There was no relationship between CSF pleocytosis and involvement outside the brachial plexus (p 5 0.15; CI 0.7–120.4).
There was no relationship between CSF pleocytosis and Functional Disability Score at final follow-up (p 5 0.15; CI 0.66–
40.6).
aOrdered logistic regression was used to compare the ordered outcomes.
bSome patients received more than one modality of immunomodulatory treatment.
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(6/31, 19.4%) when tested within this period.
These findings suggest that HEV could be
neurotropic and might directly infect the
brachial plexus and the cervical roots.
Alternatively, or in addition, HEV may induce
an immunologic response that causes nerve dam-
age or aggravates the neural injury primarily caused
by direct infection. The absence of HEV RNA in
the CSF suggests that only neural structures out-
side the intrathecal space were infected or that the
HEV had already cleared at the onset of nerve
injury. To date, there is insufficient evidence to
prove these mechanisms, although there is some
evidence from laboratory and animal studies that
supports the concept of HEV as a neurotropic
virus.21–23
We found no differences in outcomes between
groups, although we expected that the HEV-
associated NA group would have a worse progno-
sis because of the more extensive nerve damage
seen. Both groups recovered over the course of
months to years, but half of all the patients were
still in need of some form of help after 1 year.
Whether the differences in the use of immuno-
modulatory therapy influenced this outcome (HEV
cases received were more commonly given immu-
nomodulatory treatment than non-HEV cases) is
a matter of debate, but in view of the putative
immune-mediated etiology of NA, its efficacy
should be prospectively tested. Equally important
is that we did not encounter serious treatment-
related adverse events in any of the patients, and
in particular, we did not see worsening of HEV
infection in viremic patients treated with cortico-
steroids or IVIg. Nonetheless, our treatment and
outcome data need to be interpreted with caution,
as this study was not designed to define treatments
of HEV-NA. Furthermore, the outcome measures
have not been specifically validated for NA. For
example, the MRC sum-score used relies on weak-
ness in just 3 muscles and may not be able to reli-
ably distinguish between HEV-NA cases with more
extensive neurologic injury and HEV-negative
cases.
During the course of our studies of HEV-NA, we
observed cases that did not fulfill our case definition
of NA, but are worthy of discussion. An example of
such a case is as follows. A 55-year-old man from
Cornwall developed severe, progressive pain in the
right shoulder while working. Clinical assessment in
the emergency department showed no abnormal neu-
rologic signs, and he was not jaundiced. However, his
serum ALT level was found to be 572 IU/L. After 12
hours, his pain completely abated, and he developed
no further neurologic symptoms or signs. He was
found to have HEV infection, as he was anti-HEV
IgM and IgG positive, and gt3 HEV was recovered
from his serum. This case is compatible with a self-
limiting, “forme fruste” of NA. Several such cases
were seen at more than one center during our studies,
but have not been included in our data analysis. How
frequently these kinds of cases occur is not known, as
the diagnosis and underlying infectious trigger are
easily overlooked. NA has previously been considered
a rare condition, but a recent detailed analysis in
primary care in the Netherlands showed that the true
incidence may be 1:1,000 cases per year,18 forme
fruste cases (such as the one described above)
excluded. In our experience, the triad of severe bilat-
eral shoulder pain in a middle-aged man with abnor-
mal LFTs is highly predictive of the diagnosis of HEV
infection.
The main limitation of our study is its retrospec-
tive nature. In common with all retrospective studies,
there was an issue with missing data that were not
recoverable. This may have led to us to miss impor-
tant observations regarding the phenotype and out-
come in HEV-NA. Also, although our study shows
that approximately 50% of the 118 cases of NA were
associated with HEV, this may not be a true reflection
of the proportion of cases associated with HEV in the
community due to case-ascertainment bias. For
example, in the past 2 years, 41 patients with NA
have been seen in ’s-Hertogenbosch, the Netherlands,
and all prospectively tested for HEV, but only 11/41
(26.8%) had HEV infection. The opposite is true for
patients included from Southern Switzerland, where
11/13 (84.6%) had acute HEV infection. Therefore,
the proportion of NA cases associated with HEV
infection may reflect the amount of circulating virus
in a community and may vary considerably, as the
incidence and prevalence of HEV varies significantly
between and within countries and over time.7
To date, all cases of HEV-NA have been from
developed countries and, where viral sequencing data
were available, caused by HEV gt3.5 HEV is an
ancient virus, and biological time clock studies sug-
gest that it diverged into the 4 main genotypes (HEV
gt1-4) that cause human disease several hundred years
ago.24,25 It is interesting to go back to Parsonage and
Turner’s2 original description of NA, the data for
which were collected during and just after the 2nd
World War. Approximately 50% of the cases were
found in military personnel serving in South Asia,
mainly India and Burma, where HEV gt1 was circu-
lating at around the same time.26 Around 30% had
bilateral neurologic involvement, consistent with
what we now know to be the predominant HEV-
associated phenotype. It is tempting to speculate,
but quite impossible to prove, whether such cases
were also associated with HEV, possibly gt1. It is also
interesting to note that nearly half of Parsonage and
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Turner’s cases described were in individuals who were
already hospitalized, many of whom were recovering
from preceding infections including suspected
typhoid and cholera and other infections of uncertain
etiology.2 The role of infectious agents other than
HEV in NA remains to be determined.
HEV-associated NA results in a distinct clinical
phenotype with predominantly bilateral, asymmetri-
cal involvement of the brachial plexus often with
the involvement of the phrenic nerve in older men
and may be part of a spectrum of HEV-associated
(sub)acute nerve injury, including mononeuritis mul-
tiplex and Guillain-Barré syndrome.5,27 The relation-
ship between HEV and NA is likely to be causal.
Prospective studies are required to determine optimal
treatment and outcome. The diagnosis of HEV in
patients with NA is easily overlooked, as the LFTs
are sometimes normal, and the typical phenotype
described above is not universal in patients with
HEV-associated NA. We recommend that all patients
with NA be tested for HEV at presentation. This will
further improve our understanding of the prevalence,
phenotypic spectrum, and disease mechanisms of
HEV-NA cases.
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